Yale lists a Phase III enicepatide trial for adults with obesity. Learn what participation involves and which questions to ask the study team.
On a page last updated October 13, 2026, Yale’s Center for Clinical Investigation lists ENITH-1 as a Phase III study of enicepatide for adults with obesity who do not have diabetes. The listing describes an investigational once-weekly injectable that acts on GLP-1 and GIP receptors.
According to Yale, these are the central details of the study opportunity:
The practical significance is access to information about a research opportunity. For someone weighing participation, the useful starting point is the study’s actual requirements rather than an imagined result.
Roche identifies enicepatide as the investigational drug previously called CT-388. The company reports two ongoing Phase III studies in chronic weight management: ENITH-1 and ENITH-2.
There is also earlier research, but it needs to stay attached to the population that produced it. Roche’s separate Phase II study, CT-388-104, evaluated enicepatide in 447 adults with type 2 diabetes and overweight or obesity over 48 weeks.
Reuters reported Roche’s finding of an average 15.5% body-weight reduction in that study. Roche describes the Phase II findings as topline results. That figure belongs to a company-reported study involving people with diabetes, not to Yale’s ENITH-1 population without diabetes.
The evidence boundary is specific. Yale’s listing provides no ENITH-1 results or body-composition and strength outcomes. The available sources do not establish effects on muscle preservation, sexual wellbeing, appearance or long-term health in gay men aged 35 and older. The earlier Phase II result does not establish a personal weight-loss forecast for this different population.
The public listing also leaves out the study’s sample size and detailed eligibility criteria. It does not provide the dose schedule or randomization ratio. Specific endpoints and a ClinicalTrials.gov identifier are absent too. Those details belong in a conversation with the study team rather than being filled in from assumptions about other trials.
Yale lists Yweight@yale.edu and 203-737-3000 for study inquiries. Contacting the team is a request for information and eligibility assessment, not a commitment to participate or a guarantee of enrollment.
A useful inquiry can be straightforward: explain that you are asking about ENITH-1 and request the information needed to understand participation. There is no need to present yourself as the ideal candidate before the team has explained its criteria.
Bring questions that separate eligibility from expectations:
These questions do not require a decision in advance. They create a basis for one. The goal of the first conversation is to understand the offer accurately, including the parts that might make participation unsuitable for your circumstances.
For personal medical decisions, bring the information to a qualified clinician who knows your health history. The research team can explain the study; an individual care discussion can address how that opportunity fits your situation.
The once-weekly description applies to the injectable. Yale separately describes regular visits over about 1.5 years, so the practical commitment deserves its own attention.
Before deciding, ask the team to translate “regular visits” into a calendar. Find out what attendance would involve and which expectations are fixed. Work responsibilities and travel plans are reasonable parts of that conversation.
Keep the financial wording equally precise. Yale says study medication is provided at no cost to qualifying participants. Ask what other participation-related expenses or arrangements need discussion rather than reading that statement as a promise that every aspect of participation is covered.
For a man over 35, a workable decision needs room for the life he already has. Training might matter greatly to him. So might a demanding job, a partner or time with friends. None of those priorities needs to disappear from the conversation simply because the study concerns body weight.
A practical way to prepare is to write down the commitments you would need to protect. Then ask the team how participation would interact with them. This is an organizational step, not a medical screening rule or a reason to decide eligibility yourself.
The right question is not only whether the study sounds interesting. It is whether its actual demands make sense once they are visible.
For readers interested in body composition, distinguish the goals before discussing the study. Body weight is one consideration. Muscle and physical function are others. Appearance is a personal priority rather than a substitute for any of those measures.
That distinction changes the questions worth asking. Ask which outcomes the researchers will measure and whether those include body composition or physical function. Explain which aspects of daily capability matter to you so the discussion stays connected to your reasons for being interested.
You do not have to choose between caring about your appearance and taking health seriously. Wanting clothes to fit differently is a legitimate personal preference. Wanting to remain strong is another. Neither requires treating a weight-loss percentage as a complete account of success.
Related reading on keeping strength in view during fat loss can help frame the broader conversation. It should sit alongside the study information rather than substitute for answers from the research team.
Gay context belongs here without becoming a stereotype. A reader’s concerns might include confidence in dating or feeling comfortable with a partner. Another reader may be focused on physical capability and have no interest in dating at all. There is no single gay reason to pursue weight management.
If a personal sexual-health or relationship concern is part of your interest, name it in a qualified care conversation. Keep that goal visible as your own priority rather than assigning it to the study as an expected benefit.
It helps to keep two decisions distinct: whether to learn more about ENITH-1 and whether to seek weight-management care. One is an inquiry about a particular investigation. The other is a personal healthcare discussion.
For the research decision, focus on eligibility and participation requirements. For the care discussion, explain your goals and ask a qualified clinician about appropriate options. Interest in a study does not need to become a verdict on every other approach.
Think beyond the point of joining too. Asking what happens after participation ends makes the full timeline part of the decision rather than an afterthought. GayFitLab’s coverage of support after weight-management treatment addresses a related question worth keeping on the agenda.
The most useful change to a daily routine at this stage is informational: make time for the inquiry and organize the questions that matter. There is no need to rebuild your health routine around a recruitment notice. Get the study details first and use qualified care for decisions specific to you.
Treat Yale’s listing as an invitation to ask informed research questions, while keeping weight-management decisions grounded in qualified care and your separate goals for strength, appearance and daily life.
After an ENITH-1 inquiry, the next task is connecting body-composition priorities with the rest of life, a subject GayFitLab covers through research-led health reporting. For gay men 35+ whose social and sexual-health concerns are often missing from generic advice, its editorial guidance places fitness alongside confidence and relationships without prescribing one model of gay adulthood.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
